- Postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) was associated with extended PFS and OS in low-risk patients with hepatocellular carcinoma (HCC).
Why this matters
- Data on PA-TACE survival benefit have been largely limited to intermediate- and advanced-stage HCC.
- Monocentric Chinese study of 180 patients with HCC who achieved R0 status with hepatectomy; 102 underwent adjuvant PA-TACE and 78 did not (controls).
- Funding: None disclosed.
- Median follow-up, 56 months.
- Compared with control patients, PA-TRACE improved median OS (90.7 vs 54.4 months; P<.001 and vs months p>
- PA-TACE vs control, low-risk group:
- Noninvading: OS, 90.1 vs 52.8 months (P<.001 pfs vs months>
- Nonportal vein invasion: OS, 91.3 vs 52.2 months (P<.001 pfs vs months>
- Child-Pugh A: OS, 91.3 vs 65.8 months (P<.001 pfs vs months>
- Single-lesion: OS, 91.4 vs 47.2 months (P<.001 pfs vs months>
- Retrospective design.